Send to

Choose Destination
Cytokine. 2008 Dec;44(3):361-5. doi: 10.1016/j.cyto.2008.10.001. Epub 2008 Nov 17.

Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism as a potential risk factor for cardiovascular disease in hemodialyzed patients.

Author information

Department of Nephrology, Laboratory for DNA Analysis and Molecular Diagnostics, Medical University of Lublin, Dr K. Jaczewskiego 8, 20-954 Lublin, Poland.



Polymorphism in the monocyte chemoattractant protein-1 (MCP-1) gene (A-2518G) has been associated with functional effects. The aim of the present study was to assess the effect of this polymorphism on end-stage renal disease (ESRD) and cardiovascular disease (CVD) in hemodialyzed patients.


A total of 720 patients with ESRD treated with hemodialysis (450 patients with CVD) and 325 healthy control subjects were genotyped for the MCP-1 -2518 polymorphism by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) procedure.


There was a significant difference in genotype frequencies between entire group of hemodialyzed patients and controls (p<0.01). The odds ratio for the risk allele was 1.85, 95% CI 1.49-2.32 (p<0.01). Hemodialyzed patients were divided into subgroups with CVD (n=450) and without CVD (n=270). The G allele carriers occurred with significantly higher frequency in patients with CVD (62% vs. 38% in patients without CVD and 36% in controls). The odds ratio for the risk allele for patients with CVD vs. those without CVD was 2.17, 95% CI 1.71-2.79. There was no statistically significant difference in the distribution of MCP-1 genotypes between ESRD patients without CVD and healthy controls.


Our results demonstrate for the first time an association between the polymorphism in the regulatory region of the MCP-1 gene and susceptibility to CVD in hemodialyzed patients.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center